Factor H dysfunction in patients with atypical hemolytic uremic syndrome contributes to complement deposition on platelets and their activation.

No abstract is available for this paper.

• Publication year

  2008

• Venue

  Blood

• Publication date

  2008-06-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1182/blood-2007-08-106153PMID 18268093
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Implications of the progressive self-association of wild-type human factor H for complement regulation and disease.

  2008cited by this paper
• [Haemolytic uremic syndrome and thrombotic thrombocytopenic purpura: classification based on molecular etiology and review of recent developments in diagnostics].

  2008cited by this paper
• Hemolytic uremic syndrome: a factor H mutation (E1172Stop) causes defective complement control at the surface of endothelial cells.

  2007cited by this paper
• Gain-of-function mutations in complement factor B are associated with atypical hemolytic uremic syndrome

  2007cited by this paper
• Decay-Accelerating Factor Must Bind Both Components of the Complement Alternative Pathway C3 Convertase to Mediate Efficient Decay1

  2007cited by this paper
• Anti factor H autoantibodies block C-terminal recognition function of factor H in hemolytic uremic syndrome.

  2007cited by this paper
• A classification of hemolytic uremic syndrome and thrombotic thrombocytopenic purpura and related disorders.

  2006cited by this paper
• De novo gene conversion in the RCA gene cluster (1q32) causes mutations in complement factor H associated with atypical hemolytic uremic syndrome

  2006cited by this paper
• Suicidal death of erythrocytes in recurrent hemolytic uremic syndrome

  2006cited by this paper
• Structure of complement factor H carboxyl‐terminus reveals molecular basis of atypical haemolytic uremic syndrome

  2006cited by this paper
• Vacuolating megalencephalic leukoencephalopathy with subcortical cysts: functional studies of novel variants in MLC1

  2006cited by this paper
• Genetics of HUS: the impact of MCP, CFH, and IF mutations on clinical presentation, response to treatment, and outcome.

  2006cited by this paper
• Phenotypic expression of factor H mutations in patients with atypical hemolytic uremic syndrome.

  2006cited by this paper
• Lipopolysaccharide from enterohemorrhagic Escherichia coli binds to platelets through TLR4 and CD62 and is detected on circulating platelets in patients with hemolytic uremic syndrome.

  2006cited by this paper
• Platelet activation leads to activation and propagation of the complement system

  2005cited by this paper
• Anti-Factor H autoantibodies associated with atypical hemolytic uremic syndrome.

  2005cited by this paper
• Mutations in complement factor I predispose to development of atypical hemolytic uremic syndrome.

  2005cited by this paper
• VWF‐cleaving protease (ADAMTS13) in premature infants

  2005cited by this paper
• Factor H binds to washed human platelets

  2005cited by this paper
• Predisposition to atypical hemolytic uremic syndrome involves the concurrence of different susceptibility alleles in the regulators of complement activation gene cluster in 1q32.

  2005cited by this paper
• Complement factor I: a susceptibility gene for atypical haemolytic uraemic syndrome

  2004cited by this paper
• Functional analysis in serum from atypical Hemolytic Uremic Syndrome patients reveals impaired protection of host cells associated with mutations in factor H.

  2004cited by this paper
• Familial haemolytic uraemic syndrome and an MCP mutation.

  2003cited by this paper
• Complement factor H mutations and gene polymorphisms in haemolytic uraemic syndrome: the C-257T, the A2089G and the G2881T polymorphisms are strongly associated with the disease.

  2003cited by this paper
• Mutations in human complement regulator, membrane cofactor protein (CD46), predispose to development of familial hemolytic uremic syndrome

  2003cited by this paper
• Mutations in factor H reduce binding affinity to C3b and heparin and surface attachment to endothelial cells in hemolytic uremic syndrome.

  2003cited by this paper
• Sickle blood contains tissue factor-positive microparticles derived from endothelial cells and monocytes.

  2003cited by this paper
• Human cell‐derived microparticles promote thrombus formation in vivo in a tissue factor‐dependent manner

  2003cited by this paper
• Complement C3b/C3d and Cell Surface Polyanions Are Recognized by Overlapping Binding Sites on the Most Carboxyl-Terminal Domain of Complement Factor H1

  2002cited by this paper
• Haemolytic uraemic syndrome and thrombotic thrombocytopenic purpura

  2002cited by this paper
• The molecular basis for hereditary porcine membranoproliferative glomerulonephritis type II: point mutations in the factor H coding sequence block protein secretion.

  2002cited by this paper
• The molecular basis of familial hemolytic uremic syndrome: mutation analysis of factor H gene reveals a hot spot in short consensus repeat 20.

  2001cited by this paper
• Platelet activation by Shiga toxin and circulatory factors as a pathogenetic mechanism in the hemolytic uremic syndrome.

  2001cited by this paper
• First of two parts

  2001cited by this paper
• Factor H mutations in hemolytic uremic syndrome cluster in exons 18-20, a domain important for host cell recognition.

  2001cited by this paper
• Complement. First of two parts.

  2001cited by this paper
• The factor H protein family.

  1999cited by this paper
• Complement factor H gene mutation associated with autosomal recessive atypical hemolytic uremic syndrome.

  1999cited by this paper
• Role of complement in immune or idiopathic thrombocytopenic purpura

  1998cited by this paper
• CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells

  1998cited by this paper
• Specific synergy of multiple substrate-receptor interactions in platelet thrombus formation under flow.

  1998cited by this paper
• Genetic studies into inherited and sporadic hemolytic uremic syndrome.

  1998cited by this paper
• Identification of the second heparin-binding domain in human complement factor H.

  1998cited by this paper
• Complement activation occurs on subendothelial extracellular matrix in vitro and is initiated by retraction or removal of overlying endothelial cells.

  1998cited by this paper
• Pathophysiologic implications of membrane phospholipid asymmetry in blood cells.

  1997cited by this paper
• Human Factor H Deficiency

  1997cited by this paper
• Analysis of the expression of glycosylphosphatidylinositol anchored proteins on platelets from patients with paroxysmal nocturnal hemoglobinuria.

  1996cited by this paper
• Mapping of the domains required for decay acceleration activity of the human factor H‐like protein 1 and factor H

  1996cited by this paper
• Initiation of platelet adhesion by arrest onto fibrinogen or translocation on von Willebrand factor.

  1996cited by this paper
• Blockade of C5a and C5b-9 generation inhibits leukocyte and platelet activation during extracorporeal circulation.

  1995cited by this paper
• Platelet-leukocyte activation and modulation of adhesion receptors in pediatric patients with congenital heart disease undergoing cardiopulmonary bypass.

  1994cited by this paper
• Annexin V as a probe of aminophospholipid exposure and platelet membrane vesiculation: a flow cytometry study showing a role for free sulfhydryl groups.

  1993cited by this paper
• Deficiency of the GPI anchor caused by a somatic mutation of the PIG-A gene in paroxysmal nocturnal hemoglobinuria.

  1993cited by this paper
• Isolation and characterization of the complement-inhibiting protein CD59 antigen from platelet membranes.

  1992cited by this paper
• Hemolytic uremic syndrome and thrombotic thrombocytopenic purpura

  1992cited by this paper
• Direct cytotoxic action of Shiga toxin on human vascular endothelial cells

  1988cited by this paper
• Regulation of the activity of platelet-bound C3 convertase of the alternative pathway of complement by platelet factor H.

  1987cited by this paper
• Nucleated cell killing by complement: effects of C5b-9 channel size and extracellular Ca2+ on the lytic process.

  1987cited by this paper
• Thromboxane B2 synthesis in human platelets induced by the late complement components C5b-9.

  1987cited by this paper
• Human complement factor H: expression of an additional truncated gene product of 43 kDa in human liver

  1987cited by this paper
• Complement proteins C5b-9 stimulate procoagulant activity through platelet prothrombinase.

  1986cited by this paper
• Identification of a third component of complement-binding glycoprotein of human platelets.

  1986cited by this paper
• Surface membrane expression by human blood leukocytes and platelets of decay-accelerating factor, a regulatory protein of the complement system.

  1985cited by this paper
• Induction of prostanoid synthesis in human platelets by the late complement components C5b-9 and channel forming antibiotic nystatin: inhibition of the reacylation of liberated arachidonic acid.

  1985cited by this paper
• Human platelet activation by C3a and C3a des-arg

  1983cited by this paper
• Cytolysis of nucleated cells by complement: cell death displays multi-hit characteristics.

  1983cited by this paper
• Complement components in 100 newborns and their mothers determined by electroimmunoassay.

  1983cited by this paper
• Human complement in the arachidonic acid transformation pathway in platelets

  1981cited by this paper
• Human complement in thrombin-mediated platelet function: uptake of the C5b-9 complex

  1979cited by this paper
• The human complement system in thrombin-mediated platelet function

  1978cited by this paper
• Mechanism of complement-mediated activation of human blood platelets in vitro: comparison of normal and paroxysmal nocturnal hemoglobinuria platelets.

  1977cited by this paper
• Human platelet-initiated formation and uptake of the C5-9 complex of human complement.

  1976cited by this paper

• Atypical Haemolytic Uraemic Syndrome.

  2025cites this paper
• Presumed successful steroid therapy for suspected thrombotic microangiopathy in a dog.

  2025cites this paper
• From pathogenesis to immune defense: a review of repeat-in-toxins (RTX) and host response

  2025cites this paper
• Insights into membrane interactions and their therapeutic potential.

  2024cites this paper
• Deciphering Complexity: Atypical Hemolytic Uremic Syndrome Unraveled in the Wake of Elective Hip Arthroplasty

  2024cites this paper
• Complement and coagulation crosstalk - Factor H in the spotlight.

  2023influential citation
• Genetic investigation of Nordic patients with complement-mediated kidney diseases

  2023influential citation
• Underlying Genetics of aHUS: Which Connection with Outcome and Treatment Discontinuation?

  2023cites this paper
• Hemolytic uremic syndrome in the setting of COVID-19 successfully treated with complement inhibition therapy: An instructive case report of a previously healthy toddler and review of literature

  2023cites this paper
• Extracellular Vesicles and Acute Kidney Injury: Potential Therapeutic Avenue for Renal Repair and Regeneration

  2022cites this paper
• The role of anti-complement therapy in lupus nephritis.

  2022cites this paper
• The complement alternative pathway and hemostasis

  2022cites this paper
• Alternative pathway diagnostics

  2022cites this paper
• The utility of platelet activation biomarkers in thrombotic microangiopathies

  2022influential citation
• The role of properdin and Factor H in disease.

  2022cites this paper
• Differentiating and Managing Rare Thrombotic Microangiopathies During Pregnancy and Postpartum

  2022cites this paper
• Systemic complement levels in patients with age-related macular degeneration carrying rare or low-frequency variants in the CFH gene

  2021cites this paper
• Hemolytic Uremic Syndrome: “Diagnosis and Management in Pediatric Population"

  2021cites this paper
• Primary Immunodeficiency and Thrombocytopenia

  2021cites this paper
• Extracellular vesicles in renal inflammatory and infectious diseases.

  2021cites this paper
• Annexin Induces Cellular Uptake of Extracellular Vesicles and Delays Disease in Escherichia coli O157:H7 Infection

  2021cites this paper
• Factor D Inhibition Blocks Complement Activation Induced by Mutant Factor B Associated With Atypical Hemolytic Uremic Syndrome and Membranoproliferative Glomerulonephritis

  2021influential citation
• Crosstalk between the renin–angiotensin, complement and kallikrein–kinin systems in inflammation

  2021cites this paper
• MASP2 levels are elevated in thrombotic microangiopathies: association with microvascular endothelial cell injury and suppression by anti‐MASP2 antibody narsoplimab

  2020cites this paper
• Eculizumab dosing regimen in atypical HUS: possibilities for individualized treatment

  2020cites this paper
• Neutrophils from ANCA-associated vasculitis patients show an increased capacity to activate the complement system via the alternative pathway after ANCA stimulation

  2019cites this paper
• The Role of Complement in the Pathogenesis of HUS and the TMA Spectrum Disorders

  2019cites this paper
• Glomerular endothelial activation, C4d deposits and microangiopathy in immunoglobulin A nephropathy.

  2019cites this paper
• Platelets and Immune Responses During Thromboinflammation

  2019cites this paper
• A new era in hemolytic uremic syndrome. Diagnosis and treatment of a rare disease

  2019influential citation
• Monoclonal immunoglobulin–associated C3 glomerulopathy and thrombotic microangiopathy: A real association?

  2019cites this paper
• The role of anti‐complement factor H antibodies in the development of atypical haemolytic uremic syndrome: a possible contribution to abnormality of platelet function

  2019cites this paper
• Complement factor H family proteins in their non-canonical role as modulators of cellular functions.

  2019cites this paper
• Regulation of complement activation on red blood cells

  2019cites this paper
• The Human Platelet as an Innate Immune Cell: Interactions Between Activated Platelets and the Complement System

  2019cites this paper
• Consequences of dysregulated complement regulators on red blood cells.

  2018cites this paper
• Thrombotic microangiopathy after renal transplantation: Current insights in de novo and recurrent disease

  2018cites this paper
• Studies of rare genetic variants in age-related macular degeneration

  2018cites this paper
• Targeted exome sequencing in anti-factor H antibody negative HUS reveals multiple variations

  2018cites this paper
• Genotype‐phenotype correlations of low‐frequency variants in the complement system in renal disease and age‐related macular degeneration

  2018cites this paper
• Complement links platelets to innate immunity.

  2018cites this paper
• Exosomes and microvesicles in normal physiology, pathophysiology, and renal diseases

  2017cites this paper
• Atypical hemolytic uremic syndrome and C3 glomerulopathy: conclusions from a "Kidney Disease: Improving Global Outcomes" (KDIGO) Controversies Conference.

  2017cites this paper
• Worldwide Distribution of Cytochrome P450 Alleles: A Meta‐analysis of Population‐scale Sequencing Projects

  2017cites this paper
• Extracellular vesicles in renal disease

  2017cites this paper
• Factor H C-Terminal Domains Are Critical for Regulation of Platelet/Granulocyte Aggregate Formation

  2017influential citation
• Syndromes of Thrombotic Microangiopathy.

  2017cites this paper
• The complement system in age-related macular degeneration: A review of rare genetic variants and implications for personalized treatment

  2017cites this paper
• JOKIRANTA HEMOLYTIC UREMIC SYNDROME 3 Introduction Hemolytic uremic syndrome

  2017cites this paper
• Platelets and Innate Immunity in Atherosclerosis

  2017cites this paper
• Microvesicle transfer of kinin B1-receptors is a novel inflammatory mechanism in vasculitis.

  2017cites this paper
• Interaction between the metalloprotease ADAMTS-13 and the proteins of the alternative pathway of the complement system

  2017cites this paper
• Microvesicle Involvement in Shiga Toxin-Associated Infection

  2017cites this paper
• Haemolytic uraemic syndrome

  2017cites this paper
• C1-Inhibitor Decreases the Release of Vasculitis-Like Chemotactic Endothelial Microvesicles.

  2017cites this paper
• Eculizumab Dosing Regimen in Atypical HUS: Possibilities for Individualized Treatment

  2017cites this paper
• HUS and atypical HUS.

  2017cites this paper
• Actividad anti-inflamatoria e inmunomoduladora de los inhibidores solubles del complemento C4BP ß- y factor H

  2016cites this paper
• Disturbed sialic acid recognition on endothelial cells and platelets in complement attack causes atypical hemolytic uremic syndrome.

  2016cites this paper
• Fasudil inhibits tissue factor and plasminogen activator Inhibitor-1 secretion by peripheral blood mononuclear cells in CAPD patients

  2016cites this paper
• Diagnosis of complement alternative pathway disorders.

  2016cites this paper
• Clinical Practice Guidelines for the Management of Atypical Hemolytic Uremic Syndrome in Korea

  2016cites this paper
• Properdin: a tightly regulated critical inflammatory modulator

  2016cites this paper
• Dangerous liaisons: complement, coagulation, and kallikrein/kinin cross‐talk act as a linchpin in the events leading to thromboinflammation

  2016cites this paper
• Thrombotic microangiopathy and human immunodeficiency virus in the era of eculizumab

  2016cites this paper
• The role of complement activation in thrombosis and hemolytic anemias.

  2016cites this paper
• The Complement Inhibitor Factor H Generates an Anti-Inflammatory and Tolerogenic State in Monocyte-Derived Dendritic Cells

  2016cites this paper
• Adult Post–Kidney Transplant Familial Atypical Hemolytic Uremic Syndrome Successfully Treated With Eculizumab: A Case Report and Literature Review

  2016cites this paper
• Carboxiterminal pro-endothelin-1 as an endothelial cell biomarker in thrombotic thrombocytopenic purpura

  2016cites this paper
• Exploring the genetics of a complex disease: Atypical hemolytic uremic syndrome

  2016cites this paper
• REGULATION OF COMPLEMENT ACTIVATION ON SURFACES: Towards better understanding of atypical hemolytic uremic syndrome

  2016cites this paper
• The role of the complement system in the hemolytic uremic syndrome

  2015cites this paper
• Minor Role of Plasminogen in Complement Activation on Cell Surfaces

  2015cites this paper
• Thrombosis in Haematological Disorders: Tailored Management Approaches

  2015cites this paper
• Complement and platelets: Mutual interference in the immune network.

  2015cites this paper
• [Cardiac involvement in thrombotic microangiopathies].

  2015cites this paper
• Eculizumab reduces complement activation, inflammation, endothelial damage, thrombosis, and renal injury markers in aHUS.

  2015cites this paper
• Complement Interactions with Blood Cells, Endothelial Cells and Microvesicles in Thrombotic and Inflammatory Conditions.

  2015influential citation
• Thrombotic microangiopathy: focus on atypical hemolytic uremic syndrome.

  2015cites this paper
• Sensitive, reliable and easy-performed laboratory monitoring of eculizumab therapy in atypical hemolytic uremic syndrome.

  2015cites this paper
• Platelets and the complement cascade in atherosclerosis

  2015cites this paper
• From the nephrologist's point of view: diversity of causes and clinical features of acute kidney injury

  2015cites this paper
• Complement activation patterns in atypical haemolytic uraemic syndrome during acute phase and in remission

  2015cites this paper
• An international consensus approach to the management of atypical hemolytic uremic syndrome in children

  2015cites this paper
• THROMBOSIS IN HAEMATOLOGICAL DISORDERS: TAILORED MANAGEMENT APPROACHES Summary of presentations from the Alexion-supported satellite symposium held at the 20 th Congress of the European

  2015cites this paper
• The Combined Role of Galactose-Deficient IgA1 and Streptococcal IgA–Binding M Protein in Inducing IL-6 and C3 Secretion from Human Mesangial Cells: Implications for IgA Nephropathy

  2014cites this paper
• On renal pathophysiology in preeclampsia Colophon

  2014cites this paper
• Functional evaluation of factor H genetic and acquired abnormalities: application for atypical hemolytic uremic syndrome (aHUS).

  2014cites this paper
• Syndromes of thrombotic microangiopathy.

  2014cites this paper
• Comprehensive genetic analysis of complement and coagulation genes in atypical hemolytic uremic syndrome.

  2014cites this paper
• Genetics of Atypical Hemolytic Uremic Syndrome (aHUS)

  2014cites this paper
• Spectrum of Complement-Mediated Thrombotic Microangiopathies: Pathogenetic Insights Identifying Novel Treatment Approaches

  2014cites this paper
• Atypical hemolytic uremic syndrome

  2014cites this paper
• eview omplement therapy in atypical haemolytic uraemic syndrome ( aHUS ) dwin

  2013cites this paper
• Studies of ADAMTS13 expression and activity in the kidney

  2013cites this paper
• Complement therapy in atypical haemolytic uraemic syndrome (aHUS)

  2013cites this paper
• Facteurs prédictifs de récidive et de sévérité du syndrome hémolytique et urémique atypique et de la glomérulonéphrite à C3 après transplantation rénale

  2013cites this paper
• Atypical Hemolytic Uremic Syndrome

  2013cites this paper
• Murine Thrombotic Microangiopathy ADAMTS13 Deficiency in Human and Complement Activation Associated with

  2013influential citation
• The Interaction between Factor H and Von Willebrand Factor

  2013cites this paper